Home Newsfeeds William Blair Downgrades Avalara to Market Perform

William Blair Downgrades Avalara to Market Perform

William Blair analyst Bhavan Suri downgrades Avalara (NYSE:AVLR) from Outperform to Market Perform.

byBenzinga Newsdesk

August 24, 2022

1 minute read

William Blair analyst Bhavan Suri downgrades Avalara (NYSE:AVLR) from Outperform to Market Perform.

Adtran Q3 Adj. EPS $0.11 Misses $0.18 Estimate, Sales $340.71M Beat $330.39M Estimate

By Benzinga Newsdesk

November 8, 5:20 AM

Adtran (NASDAQ:ADTN) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.18 by 38.89 percent. This is a 650 percent increase over losses of $(0.02) per share from the same

ADTN

Recap: Regeneron Pharmaceuticals Q2 Earnings

By Benzinga Insights

August 3, 7:33 AM

Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q2 earnings results on Wednesday, August 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

REGN

News

Sanofi Announced Pivotal Data Demonstrate Once-weekly Efanesoctocog Alfa Provides Superior Bleed Protection Compared to Prior Factor Prophylaxis

By Charles Gross

July 10, 10:55 AM

Sanofi and Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) presented for the first time today, in a late-breaking session at the 30th International Society on Thrombosis and Haemostasis (ISTH) Congress, positive results from the XTEND-1 pivotal Phase 3 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa (BIVV001), an investigational factor VIII replacement therap

SNY